RA'ANANA, Israel, May 2, 2024
/PRNewswire/ -- Inspira™ Technologies OXY B.H.N.
Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira"),
a breakthrough medical technology company, announced the start of
production of the INSPIRA ART100 medical device.
The INSPIRA ART100 device is being contract manufactured by a
leading technology company that provides high-technology electronic
assembly solutions for the medical, aero-space and aviation,
communications and defense industries. The manufacturer has
commenced with the production and assembly of the first batch
of INSPIRA ART100 devices, which will be used for deployment in
several initial sites, subject to U.S. Food and Drug Administration
(FDA) regulatory clearance.
About Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies is an innovative medical technology
company in the respiratory treatment arena. The Company has
developed a breakthrough Augmented Respiration Technology (INSPIRA
ART), designed to rebalance patient oxygen saturation levels. This
technology potentially allows patients to remain awake during
treatment while reducing the need for highly invasive, risky, and
costly mechanical ventilation systems that require intubation and
medically induced coma. The Company's products have not yet been
tested or used in humans and has not been approved by any
regulatory entity.
For more information, please visit our corporate
website: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses the planned deployment
of its INSPIRA ART100 and its regulatory path. These
forward-looking statements and their implications are based solely
on the current expectations of the Company's management and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. Except as otherwise required by law,
the Company undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Company's annual report on Form 20-F for the
fiscal year ended December 31, 2023
filed with the U.S. Securities and Exchange Commission (the "SEC"),
which is available on the SEC's website, http://www.sec.gov
For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Logo -
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-announces-start-of-production-of-the-inspira-art100-302134546.html
SOURCE Inspira Technologies